Back to Search
Start Over
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting
- Source :
- Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 41(11)
- Publication Year :
- 2019
-
Abstract
- Background: Patient-reported outcomes (PROs) may help patients and clinicians in selecting disease-modifying therapies (DMTs) for multiple sclerosis (MS). Objective: To evaluate PRO differences among first-line DMTs for relapsing-remitting (RR) people with MS (pwMS). Methods: Multicenter study. RR pwMS on first-line DMTs completed Fatigue Severity Scale (FSS), PROs Indices for MS (PRIMUS), 36-item Short-Form Health Survey (SF-36), treatment satisfaction questionnaire for medication (TSQM), Beck Depression Inventory-II (BDI-II), and Symbol Digit Modalities Test (SDMT). Differences among PROs across DMTs were tested by ANOVA. Multivariable linear regressions were used to investigate associations between PROs and the treatment group. Results: Two-hundred eighty pwMS were enrolled: 56% were on interferons (INF), 22% on dimethylfumarate (DMF), 13% on glatiramer acetate, and 9% on teriflunomide (Teri). Compared with INF, pwMS on Teri were the oldest, with higher disability, worst depression at BDI, worst cognitive performances at SDMT (p = 0.001), fatigue at FSS (p = 0.001), and activity limitation and quality of life respectively at PRIMUS (p = 0.005) and SF-36 Mental Composite Score (p < 0.001); pwMS on DMF reported highest side effects and, together with pwMS on Teri, better treatment satisfaction at TSQM. Conclusions: Compared with INF-treated patients, pwMS on DMF and Teri reported the best treatment satisfaction, although DMF-treated pwMS reported higher side effects and those on Teri the worst QoL and fatigue; however, the older age, higher disability and depression, and worse cognitive performance of pwMS on Teri suggest to be careful in evaluating these results.
- Subjects :
- medicine.medical_specialty
Neurology
Multiple Sclerosis
Disease-modifying therapies
First-line therapies
Multiple sclerosis
Patient-reported outcomes
Dermatology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Multiple Sclerosis, Relapsing-Remitting
Teriflunomide
medicine
Humans
Multiple sclerosi
Disease-modifying therapie
030212 general & internal medicine
Effects of sleep deprivation on cognitive performance
Patient Reported Outcome Measures
Glatiramer acetate
First-line therapie
Aged
business.industry
Cognition
General Medicine
Glatiramer Acetate
medicine.disease
humanities
Psychiatry and Mental health
chemistry
Physical therapy
Quality of Life
Patient-reported outcome
Neurology (clinical)
Analysis of variance
business
030217 neurology & neurosurgery
medicine.drug
Subjects
Details
- ISSN :
- 15903478
- Volume :
- 41
- Issue :
- 11
- Database :
- OpenAIRE
- Journal :
- Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
- Accession number :
- edsair.doi.dedup.....9739ec591cc3ed52d902202e393ec70c